长春高新：子公司两款药品临床试验申请获批

Core Viewpoint - Changchun High-tech (000661) announced the approval of clinical trial applications for two products from its subsidiary, Jinsai Pharmaceutical, aimed at treating specific medical conditions [1] Group 1: Product Approvals - Jinsai Pharmaceutical's injection product GenSci140 has received approval for clinical trials, intended for the treatment of locally advanced or metastatic solid tumors [1] - The GS3-007a dry mixed suspension from Jinsai Pharmaceutical has also been approved for clinical trials, targeting growth retardation in children due to endogenous growth hormone deficiency (PGHD) [1]